Three CAR-T therapies forecasted to capture over 70 per cent of T-Cell immunotherapy market in 2025
Express Pharma
MAY 5, 2025
T-cell immunotherapies (TCI) are redefining cancer care, with chimeric antigen receptor T-cell (CAR-T) therapies witnessing significant momentum. In 2025, just three drugs- Carvykti by Legend Biotech, Yescarta by Gilead Sciences, and Breyanzi by Bristol-Myers Squibb (BMS) are expected to capture over 70 per cent of the global T-cell immunotherapy market, according to GlobalData.
Let's personalize your content